#USA #Boston #Medicilon #KRAS #Revolution Medicines

Medicilon Presents Award for Excellence in Client Partnership to Revolution Medicines

On October 30, 2026, Medicilon proudly awarded the "Excellence in Client Partnership Award" to Revolution Medicines, recognizing their strong collaborative partnership focused on innovative drug development. The award was presented during a visit by Dr. Yang Liu, the Director of Medicinal Chemistry at Revolution Medicines, and Dr. Kristof Pota, a Senior Scientist, to Medicilon's Research and Development Center in Nanhui, China. Their visit was warmly welcomed by Dr. Maosheng Duan, the Director of Medicilon's drug development division, and Dr. Jian Wang, Medicilon's Vice President.

Background of the Partnership

Over the past three years, Medicilon's team and Revolution Medicines have worked closely together to tackle various research and development challenges. This collaboration has consistently prioritized the client’s needs, focusing singularly on delivering high-quality molecular compounds efficiently. The partnership has not only created a model of trust and cooperation between the Contract Research Organization (CRO) and its client but has also demonstrated a shared commitment to success in the pharmaceutical development arena.

At the awards ceremony, Dr. Duan praised Revolution Medicines for their pioneering contributions in tackling the treatment of the previously considered "untreatable" KRAS target. This was highlighted further by the recent FDA approval of Daraxonrasib, a drug aimed at treating metastatic pancreatic cancer, which marks a significant milestone promising new hope for patients.

Recognition of Collaborative Efforts

The "Excellence in Client Partnership Award" symbolizes the trust, dedication, and achievements of both teams over more than three years of collaboration. It reflects Medicilon's confidence in their ongoing and future relationships with Revolution Medicines. During discussions, Dr. Wang elaborated on Medicilon’s growth and its integrated research and development platform, which encompasses everything from target identification to the submission of Clinical Trial Applications (IND).

In terms of quality, Medicilon meets international standards with accreditations from various regulatory bodies, including NMPA, OECD GLP, FDA GLP, and AAALAC. Their advanced platforms support a variety of programs, including Antibody-Drug Conjugates (ADC) and Targeted Protein Degradation (TPD), among others. Such robust capabilities highlight the importance of their collaborative efforts in achieving breakthrough results.

Future Opportunities for Collaboration

The visit also emphasized discussions on inter-regional data transfers, project management, future collaborations, and strategies to enhance cross-border research and development efficiency. Following the discussions, Dr. Liu and Dr. Pota toured Medicilon's state-of-the-art laboratories, witnessing firsthand the facilities for medicinal chemistry, oligonucleotide synthesis, active pharmaceutical ingredient manufacturing, and preclinical research. This tour provided invaluable insights into Medicilon's quality management systems and R&D infrastructure, further underscoring the depth of their collaboration.

Conclusion

As both Medicilon and Revolution Medicines move forward, their partnership exemplifies the importance of client collaboration and innovation in the pharmaceutical industry. With the groundwork laid over the past years, both organizations are poised for continued success, advancing healthcare solutions that significantly improve patient outcomes. The trust established through this venture not only paves the way for future projects but also sets a benchmark for other industry collaborations in the field of drug development.